Results on cross-reactivity and HLA class I restriction of RCC-reactive CTL clones isolated from healthy donors 860 and 880
. | Patients . | . | Donors . | Other individuals . | . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTL group . | RCC . | LCL PHA-B . | LCL PHA-B . | LCL PHA-B . | NKC . | K562 . | Non-RCC . | HLA restriction . | ||||
| 1 | + | + | - | + | + | - | BC, LC, PC, LK, COC, HCC, MEL | A2, A3, B44 | ||||
| 2 | + | - | - | - | - | - | COC | A2, Cw7 | ||||
| 3 | + | - | - | - | + | - | - | A2, B7, Cw7 | ||||
| 4* | + | - | - | - | + | + | MEL | Cw7 | ||||
| 5* | + | - | - | - | NT | - | BC, LC, PC, COC | lb | ||||
. | Patients . | . | Donors . | Other individuals . | . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTL group . | RCC . | LCL PHA-B . | LCL PHA-B . | LCL PHA-B . | NKC . | K562 . | Non-RCC . | HLA restriction . | ||||
| 1 | + | + | - | + | + | - | BC, LC, PC, LK, COC, HCC, MEL | A2, A3, B44 | ||||
| 2 | + | - | - | - | - | - | COC | A2, Cw7 | ||||
| 3 | + | - | - | - | + | - | - | A2, B7, Cw7 | ||||
| 4* | + | - | - | - | + | + | MEL | Cw7 | ||||
| 5* | + | - | - | - | NT | - | BC, LC, PC, COC | lb | ||||
+ indicates targets that were recognized by specific CTL clones; - indicates targets that were not recognized by specific CTL clones; LCL, EBV B-lymphoblastoid cell line; PHA-B, phytohemagglutinin-activated PBMC blasts; NKC, primary nonmalignant kidney cells; BC, breast carcinoma; LC, lung cancer; PC, pancreatic carcinoma; LK, leukemia; COC, colon cancer; HCC, hepatocellular carcinoma; MEL, melanoma; NT, not tested.
Only observed in donor 860.